Statin/Ezetimbe Combination Therapy: Emerging Evidence

More documents

Recommendations

Info

SHARP: Conclusions • No increase in risk of myopathy, liver and biliary disorders, cancer, or nonvascular mortality • No substantial effect on kidney disease progression • Two-thirds compliance with eze/simv reduced the risk of major atherosclerotic events by 17% (consistent with metaanalysis of previous statin trials) • Full compliance would reduce the risk of major atherosclerotic events by one quarter, avoiding 30–40 events per 1000 treated for 5 years
First ESC/EAS guidelines for dyslipidemia - EAS 2011 Gothenburg, Sweden ESC/EAS 2011 Guidelines Bile acid sequestrants or nicotinic acid, or a cholesterol absorportion inhibitor, either alone or in combination with bile acid sequestrants or nicotinic acid, can be considered in patients who do not tolerate statins. <strong>Statin</strong> combination therapy with either a cholesterol absorption inhibitor, bile acid sequestrant or nicotinic acid may be considered if the target level is not reached. Chronic kidney disease (CKD) is regarded as a coronary artery disease equivalent with LDL cholesterol as the primary target for treatment. <strong>Statin</strong>s are the first line treatment and also have protective effects on the rate of kidney function loss and on proteinuria. Patients with moderate to severe CKD should be considered as very high risk and clinicians should therefore aim to achieve a LDL cholesterol target of
Page 1 and 2: Statin/Ezetimbe Combination Therapy
Page 3 and 4: Recommendations for Lipid Analyses
Page 5 and 6: Cholesterol Goal Attainment in Egyp
Page 7 and 8: Cholesterol Goal Attainment in Egyp
Page 9 and 10: Why do statins alone don’t get ou
Page 11 and 12: Statins Adverse Events • Hepatoto
Page 13 and 14: Severe Adverse Event Rates for Each
Page 15 and 16: INHIBITION OF CHOLESTEROL SYNTHESIS
Page 17 and 18: Exogenous Endogenous Cholesterol Ab
Page 19 and 20: CAI THE INHIBITION OF CHOLESTEROL A
Page 21 and 22: Switching to Combination vs. Statin
Page 23 and 24: EfficACy and SafeTy of Ezetimibe Ad
Page 25 and 26: EfficACy and SafeTy of Ezetimibe Ad
Page 27 and 28: The Vytorin on CIMT and Overall Art
Page 29 and 30: A Recent Meta-analysis May 2011 27
Page 31 and 32: LDL-C Goal Achievement 100 90 80 70
Page 33 and 34: SHARP: Rationale • Risk of vascul
Page 35 and 36: Study of Heart And Renal Protection
Page 37 and 38: Proportion suffering event (%) SHAR
Page 39: Proportion suffering event (%) SHAR
Page 43: Overall Conclusion • A beneficial

Statin/Ezetimbe Combination Therapy: Emerging Evidence

Create successful ePaper yourself

Delete template?

Save as template?